Protalix Biotherapeutics, Inc. (PLX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Protalix Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases, utilizing its proprietary ProCellEx plant cell-based protein expression system. The company's primary commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). Operations are primarily conducted in Israel, where the company is designated an "essential enterprise," allowing continued operation despite regional military conflicts.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $33.75 million | $10.11 million |
| Net Income (Loss) | $18.32 million | $(3.62) million |
| Operating Income | $21.15 million | $(4.15) million |
| Cash & Equivalents | $41.00 million | $19.46 million (end of period) |
| Short-term Bank Deposits | $10.08 million | $15.59 million |
| Total Liquidity | $51.08 million | N/A |
| Operating Cash Flow | $22.03 million | $(5.06) million |
| Diluted EPS | $0.22 | $(0.05) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 234% year-over-year, driven primarily by a $25.0 million milestone payment from Chiesi Farmaceutici S.p.A. following the European Commission's approval of a new 2 mg/kg every-four-weeks (E4W) dosage for Elfabrio.
- Product Sales Variance: Revenue from selling goods decreased 26% to $7.42 million. This was due to a significant drop in sales to Pfizer ($5.53 million decrease) and Fiocruz ($0.56 million decrease), partially offset by new sales to Chiesi ($3.51 million).
- Profitability Turnaround: The company swung from a net loss of $3.62 million in Q1 2025 to a net income of $18.32 million in Q1 2026.
- Expense Growth: Research and Development (R&D) expenses increased 56% to $5.43 million, attributed to preparations for the RELEASE study. SG&A expenses rose 17% to $3.05 million.
- Tax Impact: Income tax expense was $2.82 million, primarily due to Global Intangible Low-Taxed Income (GILTI) and limitations under IRC Section 174, contrasting with a tax benefit in the prior year.
Outlook, Risks, and Management Commentary
- Liquidity: Management states that cash and short-term deposits ($51.1 million) are sufficient to fund operations for at least 12 months. No sales were made under the At-The-Market (ATM) Sales Agreement in Q1 2026; approximately $15.7 million remains available.
- Strategic Focus: The company is expanding its pipeline with early-stage candidates for renal diseases (PRX 115 for gout, PRX 119 for NETs-related diseases) and continuing the RELEASE study.
- Geopolitical Risks: Operations in Israel face risks from ongoing military conflicts involving Iran, Hamas, Hezbollah, and the Houthis. While facilities are deemed "essential," the company notes the situation remains volatile. Drug substance is stored in multiple locations to mitigate loss risk.
- Commercial Risks: Revenue recognition is tied to bulk orders from partners (Pfizer, Chiesi, Fiocruz) rather than direct patient demand, leading to potential period-to-period volatility. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement.
Investor Verification Checklist
- Milestone Sustainability: Verify the timing and likelihood of future regulatory milestones with Chiesi to assess the sustainability of the $25M revenue spike.
- Partner Order Patterns: Monitor Pfizer and Fiocruz order volumes to understand the volatility in "selling goods" revenue, which does not directly correlate with patient uptake.
- Geopolitical Exposure: Assess the potential impact of escalating Middle East conflicts on manufacturing continuity and supply chain logistics in Israel.
- R&D Burn Rate: Track the cash burn associated with the new RELEASE study and pipeline expansion against the current $51M liquidity runway.
- Tax Liability: Review the impact of U.S. tax reform (H.R.1) and GILTI on future net income, as tax expenses significantly reduced the bottom line in Q1 2026.